NVS Novartis RESULTS: Q2, Q2 net sales $14.408B vs. EST $14.042B, Q2 core EPS $2.41 vs. EST $2.13, Q2 Net Income $3.257B, Q2 core Net Income
NVS Novartis RESULTS: Q2, Q2 net sales $14.408B vs. EST $14.042B, Q2 core EPS $2.41 vs. EST $2.13, Q2 Net Income $3.257B, Q2 core Net Income $4.578B, Q2 core Operating Income $5.940B, Q2 EPS $1.71, Novartis Earnings Notes:, Full-year 2026 guidance2 reaffirmed, Net debt increased to $39.4B at June 30, 2026, compared to $21.9B at December 31, 2025, Q2 entresto sales down 50% Y/y at $1.18B
NVS Novartis RESULTS: Q2, Q2 net sales $14.408B vs.
EST $14.042B, Q2 core EPS $2.41 vs.
EST $2.13, Q2 Net Income $3.257B, Q2 core Net Income $4.578B, Q2 core Operating Income $5.940B, Q2 EPS $1.71, Novartis Earnings Notes:, Full-year 2026 guidance2 reaffirmed, Net debt increased to $39.4B at June 30, 2026, compared to $21.9B at December 31, 2025, Q2 entresto sales down 50% Y/y at $1.18B